NCT03410927: A trial that was reported late by Taiho Oncology, Inc.
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03410927 |
|---|---|
| Title | A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 6, 2018 |
| Completion date | June 9, 2022 |
| Required reporting date | June 9, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 9, 2022 |
| Days late | None |